Allergan plc (AGN) Position Decreased by Parkside Investments LLC

Parkside Investments LLC lessened its holdings in Allergan plc (NYSE:AGN) by 11.1% in the 4th quarter, HoldingsChannel reports. The firm owned 14,380 shares of the company’s stock after selling 1,790 shares during the quarter. Parkside Investments LLC’s holdings in Allergan were worth $2,352,000 at the end of the most recent reporting period.

Several other institutional investors have also made changes to their positions in the stock. Edgewood Management LLC increased its stake in shares of Allergan by 24.3% in the 3rd quarter. Edgewood Management LLC now owns 4,445,924 shares of the company’s stock valued at $911,192,000 after purchasing an additional 869,248 shares in the last quarter. Baupost Group LLC MA boosted its holdings in Allergan by 21.9% in the 3rd quarter. Baupost Group LLC MA now owns 2,964,203 shares of the company’s stock worth $607,513,000 after buying an additional 531,600 shares during the last quarter. Parnassus Investments CA boosted its holdings in Allergan by 20.4% in the 4th quarter. Parnassus Investments CA now owns 2,161,833 shares of the company’s stock worth $353,633,000 after buying an additional 365,914 shares during the last quarter. Epoch Investment Partners Inc. boosted its holdings in Allergan by 1.0% in the 3rd quarter. Epoch Investment Partners Inc. now owns 1,805,608 shares of the company’s stock worth $370,060,000 after buying an additional 17,068 shares during the last quarter. Finally, Legal & General Group Plc boosted its holdings in Allergan by 5.3% in the 3rd quarter. Legal & General Group Plc now owns 1,739,410 shares of the company’s stock worth $356,484,000 after buying an additional 87,953 shares during the last quarter. Hedge funds and other institutional investors own 80.23% of the company’s stock.

In other Allergan news, Director Christopher J. Coughlin acquired 10,000 shares of the firm’s stock in a transaction that occurred on Tuesday, December 5th. The shares were purchased at an average cost of $163.30 per share, for a total transaction of $1,633,000.00. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Chris W. Bodine acquired 3,030 shares of the firm’s stock in a transaction that occurred on Thursday, December 7th. The stock was acquired at an average price of $164.77 per share, for a total transaction of $499,253.10. The disclosure for this purchase can be found here. Over the last 90 days, insiders have bought 17,630 shares of company stock worth $2,890,057. Insiders own 0.36% of the company’s stock.

AGN has been the topic of several research analyst reports. Zacks Investment Research cut Allergan from a “hold” rating to a “sell” rating in a report on Tuesday, January 2nd. Deutsche Bank set a $251.00 price objective on Allergan and gave the stock a “buy” rating in a report on Tuesday, October 17th. TheStreet cut Allergan from a “c-” rating to a “d+” rating in a report on Monday, December 4th. JPMorgan Chase & Co. reiterated a “buy” rating and issued a $275.00 price objective on shares of Allergan in a report on Monday, October 16th. Finally, Wells Fargo & Co set a $276.00 price objective on Allergan and gave the stock a “buy” rating in a report on Friday, October 13th. Two analysts have rated the stock with a sell rating, seven have assigned a hold rating and fourteen have given a buy rating to the company’s stock. The company has a consensus rating of “Buy” and a consensus price target of $227.23.

Allergan plc (NYSE:AGN) opened at $162.57 on Friday. The firm has a market capitalization of $54,610.00, a P/E ratio of -13.56, a PEG ratio of 1.26 and a beta of 1.19. Allergan plc has a twelve month low of $160.07 and a twelve month high of $256.80. The company has a current ratio of 2.04, a quick ratio of 1.08 and a debt-to-equity ratio of 0.41.

Allergan (NYSE:AGN) last issued its earnings results on Tuesday, February 6th. The company reported $4.86 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $4.74 by $0.12. The business had revenue of $4.33 billion for the quarter, compared to analysts’ expectations of $4.28 billion. Allergan had a positive return on equity of 8.28% and a negative net margin of 26.32%. The business’s revenue for the quarter was up 12.0% compared to the same quarter last year. During the same period in the previous year, the firm posted $3.90 EPS. research analysts predict that Allergan plc will post 15.44 earnings per share for the current year.

The business also recently announced a quarterly dividend, which will be paid on Wednesday, March 28th. Stockholders of record on Wednesday, February 28th will be issued a dividend of $0.72 per share. This is a boost from Allergan’s previous quarterly dividend of $0.70. This represents a $2.88 annualized dividend and a dividend yield of 1.77%. Allergan’s payout ratio is currently -23.35%.

ILLEGAL ACTIVITY WARNING: “Allergan plc (AGN) Position Decreased by Parkside Investments LLC” was first reported by Community Financial News and is the property of of Community Financial News. If you are accessing this piece of content on another website, it was stolen and reposted in violation of U.S. & international copyright law. The original version of this piece of content can be viewed at https://www.com-unik.info/2018/02/09/allergan-plc-agn-position-decreased-by-parkside-investments-llc.html.

About Allergan

Allergan, Inc is a multi-specialty healthcare company. The Company focuses on developing and commercializing pharmaceuticals, biologics, medical devices and over-the-counter (OTC) products. It discovers, develops and commercializes a range of products for the ophthalmic, neurological, medical aesthetics, medical dermatology, breast aesthetics, urological and other specialty markets.

Want to see what other hedge funds are holding AGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Allergan plc (NYSE:AGN).

Institutional Ownership by Quarter for Allergan (NYSE:AGN)

Receive News & Ratings for Allergan Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allergan and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit